1261629-96-2 Usage
Uses
Used in Pharmaceutical Industry:
Ethyl 4-hydroxyquinoline-7-carboxylate is used as an antimalarial agent for treating malaria caused by Plasmodium species. It is effective due to its ability to inhibit heme polymerase, which is crucial for the survival of the malarial parasite.
Used in Autoimmune Disorders:
Ethyl 4-hydroxyquinoline-7-carboxylate is used as an immunosuppressive agent for managing autoimmune disorders. It is believed to dampen the immune response, providing relief from symptoms associated with these conditions.
Used in Anti-inflammatory Applications:
Ethyl 4-hydroxyquinoline-7-carboxylate is used as an anti-inflammatory agent, potentially inhibiting the production and release of pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6, which play a role in the inflammatory response.
Used in Research:
Ethyl 4-hydroxyquinoline-7-carboxylate is used as a research tool in studying the mechanisms of action of antimalarial drugs, as well as in investigating the role of heme polymerase in various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1261629-96-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,1,6,2 and 9 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1261629-96:
(9*1)+(8*2)+(7*6)+(6*1)+(5*6)+(4*2)+(3*9)+(2*9)+(1*6)=162
162 % 10 = 2
So 1261629-96-2 is a valid CAS Registry Number.
1261629-96-2Relevant articles and documents
PRMT5 INHIBITORS
-
Page/Page column 79-80, (2021/06/26)
The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.